We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more here.Close Me
On July 12, 2017, EFSA issued a report on the re-evaluation of group of
glutamates (E 620-625) used as flavor enhancers. EFSA concluded
that no adverse effects were observed in the available short-term,
subchronic, chronic, reproductive, and developmental studies.
However, EFSA stated that glutamates are widely associated with
adverse effects, such as headache, raised blood pressure, and
increased insulin levels, for some population groups. Thus, EFSA
used the available neurodevelopmental toxicity study to derive a
group acceptable daily intake ("ADI") of 30 mg/kg bw per
day. Importantly, EFSA also noted that the current exposure to
glutamate exceeded not only the proposed ADI but also doses
associated with the adverse effects mentioned above. EFSA report is
likely to lead in the future to the revision of the permitted
levels of glutamates in foods in the European Union.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Legal adult-use marijuana is associated with risks that may cause bodily injury and property damage. Many of these risks have been well documented and widely discussed in the media, ...
On September 14, the Centers for Medicare & Medicaid Services (CMS) announced its newly designed Medicare card and informed all Medicare beneficiaries to look for their new card in the mail.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Earlier this month, Mintz Levin's Health Care Enforcement Defense Group published its most recent Health Care Qui Tam Update that looks at 23 health care-related qui tam cases unsealed in June 2017.
The "rigorous" materiality requirement in False Claims Act cases post-Universal Health Servs., Inc. v. United States ex rel. Escobar just cost a relator millions of dollars.
While September 30, 2017 has been an important procedural deadline for purposes of the GOP's most recent legislative push to repeal the Affordable Care Act (ACA), it also serves a critical funding...
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Value-based Health Care: Issues For Pharmaceutical Companies (Video)
